- Evonik's new site in Tours will produce commercial quantities of plant extracts.
- The site will develop tailored products and offer its own products from 2018.
- Evonik's portfolio includes ceramides, sphingolipids, and peptides.
- The technology allows high-yield extraction of bioactive substances without modifying plant genomes.
New Site in Tours
Evonik has opened a new site for its Evonik Advanced Botanicals subsidiary in Tours, France. This site is part of the Personal Care Business Line and was established following the acquisition of Alkion Biopharma SAS in 2016. The new facility aims to become a center for plant-based active ingredients, leveraging its location in the 'Cosmetic Valley' and collaboration opportunities with the University of Tours.
Technological Advancements
Evonik's new site will focus on producing commercial quantities of plant extracts using advanced biotechnological processes. The technology developed allows for the cultivation of plant biomass under laboratory conditions, achieving high yields of complex ingredients without modifying the plant genome. This results in plant extracts with a high concentration of desired bioactive substances.
Product Portfolio
The company's existing portfolio includes ceramides, sphingolipids, and peptides. The addition of plant-based active ingredients will enable Evonik to offer tailored, high-performance products in concentrated and reproducible forms. Many customer projects for these tailored products are already at an advanced stage.
Future Plans
Evonik plans to start offering its own products developed at the new Tours facility from 2018. Representatives from cosmetic manufacturers, the University of Tours, and local authorities attended the opening ceremony to learn about the innovative technology and express their support for the new site.
